JAK INGIBITORLARI: TA’SIR MEXANIZMI, FARMAKOLOGIK XUSUSIYATLARI VA ZAMONAVIY KLINIK QO’LLANILISHI
DOI:
https://doi.org/10.5281/zenodo.21062480Kalit so‘zlar:
JAK ingibitorlari, Janus kinaza, JAK–STAT signal yo’li, farmakologiya, farmakodinamika, farmakokinetika, autoimmun kasalliklar, revmatoid artrit, psoriatik artrit, yarali kolit, immunomodulyatsiya, biologik nishonli terapiyaAbstrak
Janus kinaza (JAK) ingibitorlari autoimmun va surunkali yallig‘lanish kasalliklarini davolashda qo‘llanilayotgan zamonaviy dori vositalari guruhlaridan biri hisoblanadi. Ushbu preparatlar hujayra ichidagi JAK–STAT signal uzatish yo‘lini selektiv ravishda bloklash orqali sitokinlar ta’sirini kamaytiradi hamda yallig‘lanish jarayonini nazorat qiladi. Mazkur maqolada JAK ingibitorlarining ta’sir mexanizmi, farmakodinamik va farmakokinetik xususiyatlari, klinik qo‘llanilishi, nojo‘ya ta’sirlari hamda zamonaviy farmakoterapiyadagi o‘rni ilmiy adabiyotlar asosida tahlil qilindi. Shuningdek, turli avlod JAK ingibitorlarining o‘ziga xos jihatlari, ularning samaradorligi va xavfsizlik profili yoritilib, kelgusidagi ilmiy izlanishlarning istiqbolli yo‘nalishlari muhokama qilindi. Tahlil natijalari JAK ingibitorlari ko‘plab autoimmun kasalliklarda samarali terapevtik vosita ekanligini, biroq ularni qo‘llashda bemorning individual xususiyatlari va ehtimoliy nojo‘ya ta’sirlarni hisobga olish zarurligini ko‘rsatadi.
Foydalanilgan adabiyotlar
1. Brunton L.L., Hilal-Dandan R., Knollmann B.C. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
2. Katzung B.G., Vanderah T.W. Basic and Clinical Pharmacology. 16th ed. New York: McGraw-Hill Education; 2024.
3. Rang H.P., Ritter J.M., Flower R.J., Henderson G. Rang & Dale’s Pharmacology. 10th ed. Elsevier; 2024.
4. O’Shea J.J., Gadina M., Siegel R.M. Cytokines and Cytokine Receptors. In: Paul’s Fundamental Immunology. 8th ed.
5. Schwartz D.M., Kanno Y., Villarino A., Ward M., Gadina M., O’Shea J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery. 2017;16(12):843–862.
6. O’Shea J.J., Holland S.M., Staudt L.M. JAKs and STATs in immunity, immunodeficiency, and cancer. New England Journal of Medicine. 2013;368(2):161–170.
7. Smolen J.S., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. 2023.
8. World Health Organization (WHO). WHO Model List of Essential Medicines. Geneva: WHO.
9. European Medicines Agency (EMA). Medicines. https://www.ema.europa.eu
10. U.S. Food and Drug Administration (FDA). Drug Safety Communications. https://www.fda.gov/drugs
11. British National Formulary (BNF). Joint Formulary Committee. London: BMJ Group and Pharmaceutical Press.
12. Lexicomp Online. Drug Monographs: Tofacitinib, Baricitinib, Upadacitinib.
